Focused Wealth Management Inc Sells 446 Shares of Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Focused Wealth Management Inc trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,929 shares of the company’s stock after selling 446 shares during the period. Focused Wealth Management Inc’s holdings in Merck & Co., Inc. were worth $836,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. NumerixS Investment Technologies Inc grew its position in Merck & Co., Inc. by 138.7% in the second quarter. NumerixS Investment Technologies Inc now owns 32,468 shares of the company’s stock worth $2,722,000 after acquiring an additional 18,868 shares in the last quarter. Girard Partners LTD. boosted its holdings in shares of Merck & Co., Inc. by 2.7% during the 2nd quarter. Girard Partners LTD. now owns 103,298 shares of the company’s stock worth $8,661,000 after buying an additional 2,720 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Merck & Co., Inc. by 15.9% during the 2nd quarter. Alps Advisors Inc. now owns 38,470 shares of the company’s stock worth $3,226,000 after buying an additional 5,273 shares during the period. Lowe Wealth Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 12.0% during the 2nd quarter. Lowe Wealth Advisors LLC now owns 1,396 shares of the company’s stock worth $117,000 after buying an additional 150 shares during the period. Finally, Bartlett & Co. LLC boosted its holdings in shares of Merck & Co., Inc. by 7.0% during the 2nd quarter. Bartlett & Co. LLC now owns 96,074 shares of the company’s stock worth $8,056,000 after buying an additional 6,271 shares during the period. 74.64% of the stock is owned by institutional investors.

Merck & Co., Inc. stock traded up $0.84 during mid-day trading on Tuesday, reaching $84.12. The company had a trading volume of 7,583,401 shares, compared to its average volume of 10,067,262. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $87.35. The company has a 50 day moving average of $83.95 and a 200-day moving average of $82.87. The firm has a market cap of $212.82 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 1.81 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 48.16%. The firm had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same period in the prior year, the firm earned $1.19 EPS. The business’s revenue was up 14.9% on a year-over-year basis. On average, analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

MRK has been the subject of several recent analyst reports. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. set a $96.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Leerink Swann initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They set an “outperform” rating and a $103.00 price objective for the company. Societe Generale set a $105.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Bank of America initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $95.13.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ValuEngine Upgrades Fresnillo  to Buy
ValuEngine Upgrades Fresnillo to Buy
Pfenex  Stock Rating Upgraded by Zacks Investment Research
Pfenex Stock Rating Upgraded by Zacks Investment Research
Algonquin Power & Utilities  Cut to “Sector Perform” at Howard Weil
Algonquin Power & Utilities Cut to “Sector Perform” at Howard Weil
Glacier Bancorp, Inc.  Announces $0.29 Quarterly Dividend
Glacier Bancorp, Inc. Announces $0.29 Quarterly Dividend
Brokerages Expect Heico Corp  Will Announce Earnings of $0.57 Per Share
Brokerages Expect Heico Corp Will Announce Earnings of $0.57 Per Share
Huntington Ingalls Industries Inc  Expected to Announce Earnings of $4.32 Per Share
Huntington Ingalls Industries Inc Expected to Announce Earnings of $4.32 Per Share


 
© 2006-2019 Zolmax.